Group 1 - The core announcement is that Kelun Pharmaceutical has had five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 [2] - The announcement was made on the evening of December 8, indicating the company's proactive communication regarding its product portfolio [2] - The inclusion in the drug list is a significant development for the company, potentially enhancing its market access and revenue opportunities [2] Group 2 - The announcement was made by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [2] - The notification regarding the drug list was officially published on December 7, 2025 [2] - This inclusion reflects the government's ongoing efforts to expand access to essential medications for the population [2]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. and its subsidiaries have five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to enhance market expansion and sales scale for the company [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice regarding the 2025 drug catalog [1] - The inclusion of the company's products in the 2025 drug catalog is anticipated to positively impact the company's market network and sales [1] - The official implementation date for the 2025 drug catalog is set for January 1, 2026, with further details on reimbursement standards to be provided by relevant government departments [1]

Core Viewpoint - Kolun Pharmaceutical has announced that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1: Financial Impact - The total sales revenue of the aforementioned drugs for the year 2024 is approximately 51.69 million yuan [1] - For the first half of 2025, the combined sales revenue is expected to be around 309.75 million yuan [1] - These sales figures represent approximately 0.24% and 3.41% of the company's revenue for the respective periods [1]